Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | Aplastic Anemia & MDS International Foundation
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

Clinical Trial: NCT02145039

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is a treatment guideline for HLA-Haploidentical hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) regimen. This regimen, consisting of fludarabine, cyclophosphamide and low dose total body irradiation (TBI), is designed for the treatment of patients with advanced and/or high risk diseases.

Status: 
Recruiting
Study Date: 
Wed, 10/01/2014 to Mon, 06/01/2020
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Fludarabine Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant. Other Name: Fludara Drug: Cyclophosphamide Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant. Radiation: Total Body Irradiation TBI 200cGy on day -1 before transplant. Other Name: TBI Biological: Haploidentical stem cell transplant Non-T-cell depleted bone marrow infusion Other Name: HSCT